Genomics Biotech

MassBio data and industry signals show a funding gap: investors prefer later-stage biotech. What this means for AI-driven biotech startups and funding strategy.

AI is accelerating drug discovery, gene editing, and synthetic biology faster than rules can adapt. A risk-tiered, adaptive governance model is needed.

Stanford deployed 37,000 AI agents to create a ‘virtual biotech’ that simulates research teams, analyzes clinical trials and speeds identification of therapeutic strategies.

Biotech investors must stop treating clinical entry as the definitive proof of AI drug discovery. Learn the AI-native milestones and KPIs that better predict long-term value.

Patrick Vallance will chair the UK AI task force as CEOs depart Legend Biotech and Sarepta. Read a concise analysis of what this means for AI and biotechnology.

Foundation AI models trained on multimodal biomedical data are speeding target discovery, improving diagnostics, and reshaping clinical trials in precision medicine.

Shanghai and Hong Kong launch a cross-border AI and biotech bootcamp that pairs Hong Kong R&D with Shanghai commercialization to speed health AI innovations to market.

SUIC and VisionRenu sign an MOU to advance AI-driven biotech and precision medicine, applying DBTL, gene editing, and ophthalmic and brain-health tech for global markets.

ChemT Biotechnology raised $4M to scale CelMo, an AI virtual cell that models CHO, T cells and more to speed, lower cost and raise yields in biologics production.

Puma Biotechnology director Troy Wilson sold 77,748 shares under a 10b5-1 plan amid recent RSU vesting. We break down the trade, Q1 2026 miss, and valuation view.